Lenalidomide Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering the degradation of specific transcription factors. This results in reduced production of pro‑inflammatory cytokines, inhibition of new blood‑vessel formation, and activation of T‑cell and natural‑killer cell activity, ultimately leading to apoptosis of malignant cells.

The specific dose of Lenalidomide Zentiva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Only a qualified healthcare professional can set the appropriate regimen, and patients should follow the prescription exactly as written.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of childbearing potential must use effective contraception. The drug is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant.

To request Lenalidomide Zentiva, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, then replies with pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Lenalidomide belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, anti‑angiogenic effects, and immune activation, which can be advantageous in certain relapse settings. Choice of therapy depends on prior treatment history, patient tolerance, and disease characteristics.

Lenalidomide Zentiva tablets should be stored at temperatures below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Lenalidomide Zentiva is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Additionally, there is a risk of secondary primary malignancies and rare severe skin reactions like Stevens‑Johnson syndrome.

Lenalidomide Zentiva should not be used by individuals who are pregnant, nursing, or have known hypersensitivity to lenalidomide or any of its excipients. It is also contraindicated in patients with uncontrolled infections or severe renal impairment without appropriate dose adjustment, as determined by a qualified clinician.